Recently, superior efficacy of denosumab, a human monoclonal antibody to the receptor activator of nuclear factor kappa-B ligand (RANKL), for the treatment of osteoporosis in the general population has been reported. This evidence concerns the gene TNFSF11 and osteoporosis.